Abstract
Executive Summary
Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the
biotechnology industry to deliver on the promise of targeted cancer drugs.
However, these three successful drugs are just the top of an emerging line of
therapy. Given the fact that they all target tyrosine kinases and that kinase
mutations can cause patients to become resistant to these drugs, there is
plenty of room for more competition.
There are today at least 360 protein kinase inhibitors in active development
for the treatment of cancer, from early preclinical to marketed drugs. In
addition, the accumulated number of ceased drugs over the last three years
amount to another 135 drugs. Protein Kinase Inhibitors in Oncology: Drug
Pipeline Update lists all drugs and gives you a progress analysis on each one
of them. Identified drugs are linked to 134 different targets. These targets
are further categorized on the CD-ROM by 31 classifications of molecular
function and with pathway referals to BioCarta, KEGG and NetPath. Read more
below on how the Protein Kinase Inhibitors in Oncology: Drug Pipeline Update
is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
- Drug Pipeline Update is delivered to you as a CD-ROM application, which
requires no installation on your computer.
| 
View Cart
